The Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridaemia (sHTG) have met their primary endpoint of TG reduction versus placebo and all prespecified secondary endpoints, including a statistically significant reduction in acute pancreatitis (AP) compared to placebo.
Risk weighted apoB improves CHD risk stratification
Risk weighted apoB (RW-apoB), a novel measure that integrates the particle number and atherogenic potential of LDL, triglyceride rich lipoprotein (TRL) and Lp(a), more accurately reflects total atherogenic burden and coronary heart disease (CHD) risk than LDL-C, non-HDL-C or apoB alone. This is the conclusion of Professor Jan Borén and colleagues from results with the […]
Tryngolza (olezarsen) is approved for sHTG in USA
The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridaemia (sHTG), ie. TG ≥500 mg/dL.
Redemplo (plozasiran) receives EU approval for FCS treatment
Redemplo (plozasiran) has been approved by the European Commission (EC) for use as an adjunct to diet to reduce TG levels in adult patients diagnosed with familial chylomicronaemia syndrome (FCS) according to clinical criteria or genetic testing.
Plozasiran prevents recurrent pancreatitis in most severe hypertriglyceridaemia
A post hoc analysis of data from the PALISADE trial has shown that plozasiran 25 or 50 mg s.c. quarterly for 12 months reduces recurrent pancreatitis in patients with familial chylomicronaemia syndrome (FCS) with a history of acute pancreatitis (AP) and the most extreme hypertriglyceridaemia.
TRL-C level may indicate fibrate benefit for atherosclerosis risk
Statin-treated individuals with elevated triglyceride-rich lipoprotein cholesterol (TRL-C) may be more likely to benefit from additional fibrate treatment, according to results of a study of 67,662 statin-treated adults without baseline atherosclerotic cardiovascular disease (ASCVD) from the Korean National Health Insurance Service cohort.
